Novo Nordisk today announced that the Food and Drug Administration has approved the new drug application for Saxenda , the first once-daily glucagon-like peptide-1 receptor agonist for chronic weight management. Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or who are overweight in the presence of at least one weight-related comorbid condition.